All In Biotech

Drug Trial Radar · NCT07944846

A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children Under General Anesthesia

A Prospective,Multicenter,Observational Study to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children Undergoing General Anesthesia

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Jun 18, 2026

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective multicenter observational study enrolls children aged 2-17 years receiving preoperative anxiolysis and separation support prior to general anesthesia. Subjects receive intranasal dexmedetomidine spray (1-2.5 μg/kg). Key assessments include Ramsay sedation score within 45 min post-drug, intraoperative MSS aspiration risk score, postoperative agitation, mYPAS/GAD-7 anxiety, PedSQoR recovery and behavioral scores, plus ongoing adverse event documentation (respiratory depression, bradycardia, etc.). The primary aim is to assess real-world efficacy and safety of intranasal dexmedetomidine across pediatric age groups and optimize medication strategies for pediatric comfortable anesthesia. Safety follow-up lasts from consent signing until 7 days after Visit 8.

Conditions

  • Preoperative Anxiety in Children

Interventions

  • Dexmedetomidine hydrochloride nasal sprayDrug

    1-2.5μg/kg,Preoperative intranasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants achieving Ramsay Sedation Score ≥3 at least once within 45 minutes after drug administrationTime frame: Within 45 minutes after intranasal dexmedetomidine administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.